Catalyst Capital Advisors’s Unity Biotechnology UBX Stock Holding History

Catalyst Capital Advisors’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-48	Closed	-$8K	–	493
2018 Q3	$8K	Hold	48	–	–	﹤0.01%	354
2018 Q2	$7K	Buy	+48	New	+$7.02K	﹤0.01%	407

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PIM

Partner Investment Management San Francisco, California $13.9M AUM 55.92% 1-Year Est. Return

Catalyst Capital Advisors's UBX Position: Q4 2018 in Review

Catalyst Capital Advisors sold out of Unity Biotechnology (UBX) in Q4 2018, closing a stake of 48 shares — an estimated $8K sold.

Catalyst Capital Advisors first reported a position in UBX in Q2 2018 and held it in 2 quarters. The position peaked at $8K in Q3 2018. 55 funds tracked by Wall St. Rank hold UBX as of Q4 2018.

Catalyst Capital Advisors reported no remaining Unity Biotechnology position as of Q4 2018 after selling out during the quarter.
Catalyst Capital Advisors sold 48 Unity Biotechnology shares in Q4 2018, an estimated $8K.
Catalyst Capital Advisors first reported a position in Unity Biotechnology in Q2 2018 and held it in 2 quarters.
Catalyst Capital Advisors's Unity Biotechnology position peaked at $8K in Q3 2018.
55 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2018.

Based on Catalyst Capital Advisors's 13F filing for Q4 2018, filed 7 Feb 2019.